Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

NCT06514534 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia (CML)

Interventions

DRUG: ABL001/Asciminib

Sponsor

Novartis Pharmaceuticals